---
title: Study of Cervix and Inflammation in Preterm Birth Prediction
nct_id: NCT01007513
overall_status: COMPLETED
sponsor: Université de Sherbrooke
study_type: OBSERVATIONAL
primary_condition: Preterm Birth
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01007513.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01007513"
ct_last_update_post_date: 2012-03-29
last_seen_at: "2026-05-12T06:08:14.386Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study of Cervix and Inflammation in Preterm Birth Prediction

**Official Title:** Cervical Assessment by Supracervical, Cervical and Vaginal Markers: Simultaneous Transvaginal Ultrasound and Inflammatory Proteins Detection

**NCT ID:** [NCT01007513](https://clinicaltrials.gov/study/NCT01007513)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Université de Sherbrooke
- **Conditions:** Preterm Birth
- **Start Date:** 2008-06
- **Completion Date:** 2009-12
- **CT.gov Last Update:** 2012-03-29

## Brief Summary

Preterm birth rate is 7.2% in Quebec, it's risen worldwide in the past decade and it's the leading cause of perinatal mortality and morbidity. Preterm birth is a major public health problem. Preterm labor leading to preterm birth is difficult to diagnose and prediction of preterm birth is a medical challenge. In the past years, research found that transvaginal ultrasound to assess the cervix of the uterus and vaginal detection of inflammatory protein, specific bacteria and fetal fibronectin can help to detect women at increase risk of preterm delivery. The investigators believe that a combination of these tests can lead to a better prediction of preterm delivery. The investigators want to conduct a study among women judged at increase risk of preterm delivery by their physician (having contractions, modified cervix, past-history of preterm delivery or multiple pregnancy) and assess their cervix by ultrasound and sample their vaginal secretion. The investigators want to analyze the vaginal sampling and look for inflammatory proteins. The objective of this study is to prove the feasibility of this assessment method and elaborate a better predictive test that the investigators can easily use in obstetrics clinics and hospitals.

## Detailed Description

Preterm birth rate in Quebec is 7.2% and, despite extensive research, the rate of preterm birth has risen worldwide over the past decades. Preterm birth is, all over the world, the first cause of perinatal mortality and morbidity. Spontaneous preterm birth (sPTB) groups premature births with intact and ruptured membranes and represents 70% of preterm delivery. The two conditions associated with sPTB share a common physiopathology and a progressive cascade of events. Extensive evidence supports a central role for the production of prostaglandins, inflammatory cytokines and matrix metalloproteinases (MMP) in the cervix and decidua to promote cervical ripening and decidual and fetal membrane activation but, the exact progression of events remains unclear. Several factors were described as risk factor for sPTB like bacterial vaginosis, inflammatory cytokines and fetal fibronectin in vaginal secretions. The transvaginal ultrasound of the cervix (TVUS), which estimates the length and the aspect of the cervix, can be used as predictive factor of preterm birth. To date, no study has addressed the supra-cervical region by transvaginal ultrasound. This region may be an important key of the inflammatory process leading to sPTB. The assessment of this region by ultrasound can be a predictive marker of sPTB. We want to prove the feasibility of this new approach of sPTB prediction : the transvaginal ultrasound assessment of the supracervical and cervical region associated with detection of vaginal inflammation.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 45 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Live singleton or multiple pregnancy
* Clinical risk of preterm delivery
* Pregnancy between 20 and 34 gestational weeks

Exclusion Criteria:

* Delivery on the day of the ultrasound
* Major fetal anomaly
* Previa placentation
```

## Arms

- **At risk patient for preterm delivery** — Patient referred to the MFM clinic for a risk evaluation for preterm delivery.

## Interventions

- **Transvaginal ultrasound** (PROCEDURE) — A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
- **Vaginal secretion sampling** (PROCEDURE) — Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.

## Primary Outcomes

- **Preterm birth < 34 gestational weeks among patient with presence of supracervical factor at ultrasound study.** _(time frame: December 2009)_

## Secondary Outcomes

- **Presence of inflammatory proteins in vaginal secretion of patient with presence of supracervical factors at transvaginal ultrasound.** _(time frame: December 2009)_
- **Neonatal morbidity of preterm infant.** _(time frame: December 2009)_

## Locations (1)

- Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada

## Recent Field Changes (last 30 days)

- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.centre hospitalier universitaire de sherbrooke|sherbrooke|quebec|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01007513.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01007513*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*